首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccl22 |
| Uniprot No | O00626 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-93aa |
| 氨基酸序列 | GPYGANMEDS VCCRDYVRYR LPLRVVKHFY WTSDSCPRPG VVLLTFRDKE ICADPRVPWV KMILNKLSQ |
| 预测分子量 | 8.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL22重组蛋白的3篇参考文献的简要概括：
---
1. **文献名称**: *CCL22 regulates T cell immunity in tumor-draining lymph nodes*
**作者**: Ishida T, et al.
**摘要**: 研究揭示了重组CCL22蛋白在肿瘤引流淋巴结中募集调节性T细胞(Tregs)的作用，证实其通过CCR4受体介导免疫抑制微环境，促进肿瘤免疫逃逸。
---
2. **文献名称**: *Production and functional characterization of recombinant human CCL22/MDC*
**作者**: Imai T, et al.
**摘要**: 该文献描述了重组人CCL22蛋白在大肠杆菌中的高效表达与纯化方法，并验证其体外趋化活性，证明其可特异性吸引表达CCR4的Th2细胞和Tregs。
---
3. **文献名称**: *CCL22 promotes ovarian cancer cell metastasis via integrin αvβ3 signaling*
**作者**: Zhang Y, et al.
**摘要**: 研究发现重组CCL22蛋白通过激活肿瘤细胞表面的整合素αvβ3信号通路，增强卵巢癌细胞的迁移和侵袭能力，提示其作为癌症治疗潜在靶点。
---
如需更多文献或具体DOI信息，可进一步补充关键词或研究场景细化检索。
Ccl22 (C-C motif chemokine ligand 22), also known as macrophage-derived chemokine (MDC) or STCP-1. is a small secretory protein belonging to the CC chemokine family. It is primarily produced by dendritic cells, macrophages, and certain epithelial cells, playing a pivotal role in immune regulation by mediating leukocyte migration and activation. Ccl22 specifically binds to the CCR4 receptor, which is highly expressed on regulatory T cells (Tregs) and type 2 helper T (Th2) cells. This interaction facilitates the recruitment of these immune cells to inflammatory or tumor microenvironments, contributing to both immune homeostasis and pathological processes like immune evasion in cancer.
Recombinant Ccl22 protein is generated through genetic engineering techniques, typically using bacterial or mammalian expression systems to ensure proper folding and post-translational modifications. The purified protein retains the functional activity of native Ccl22. enabling researchers to study its biological effects in vitro and in vivo. Applications include investigating chemotaxis assays, Treg-mediated immunosuppression, and immune cell signaling pathways. It also serves as a tool to explore therapeutic strategies targeting the Ccl22-CCR4 axis, such as blocking tumor-associated immunosuppression or modulating allergic responses.
In cancer research, elevated Ccl22 levels are linked to poor prognosis, as tumors exploit this chemokine to attract Tregs that suppress anti-tumor immunity. Conversely, in autoimmune or allergic diseases, inhibiting Ccl22 may reduce harmful inflammatory responses. Recombinant Ccl22 thus bridges basic research and translational studies, offering insights into immune modulation and potential therapeutic interventions. Quality control assays, including SDS-PAGE and functional bioactivity tests, ensure batch consistency for experimental reproducibility.
×
